Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN 21 1 50 versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN 21 1 50 versus TAYTULLA.
NORLESTRIN 21 1/50 vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (LH, FSH). Enhances cervical mucus viscosity, reducing sperm penetration. Thins endometrium, decreasing implantation likelihood.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (1 mg norethindrone acetate/50 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off therapy.
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Norethindrone terminal half-life: 5-14 hours; ethinyl estradiol terminal half-life: 10-20 hours. Clinical context: steady-state reached within 5-7 days, clinically significant for missed dose management.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Norethindrone: renal (33% as metabolites), fecal (50%); ethinyl estradiol: renal (40% as glucuronide conjugates), fecal (60%)
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive